@abhishek1004.bsky.social
Reposted
❤️Check out the VA for the discussion on the AHA/ACC Hypertension Guidelines 9/16/25 at 9pm EST by @sejalplakhani.bsky.social #NephJC #NephSky #MedSky
www.nephjc.com/news/2025/9/ahaacc-htnguide
www.nephjc.com/news/2025/9/ahaacc-htnguide
The AHA/ACC 2025 Hypertension Guidelines visual abstract — NephJC
New updated guidance on hypertension including screening for secondary causes, use of renal denervation, hypertension and pregnancy, risk assessment, monitoring and treatment. Check out this wonderfu...
www.nephjc.com
September 16, 2025 at 11:47 AM
❤️Check out the VA for the discussion on the AHA/ACC Hypertension Guidelines 9/16/25 at 9pm EST by @sejalplakhani.bsky.social #NephJC #NephSky #MedSky
www.nephjc.com/news/2025/9/ahaacc-htnguide
www.nephjc.com/news/2025/9/ahaacc-htnguide
Reposted
⏰2 hours until #NephJC chat
🔍 Tonight we are talking about the 2025 ACC/AHA Blood Pressure guidelines! Eight years have passed since the last update. What’s different? What’s the same? Tonight we tackle it all!
🔍 Tonight we are talking about the 2025 ACC/AHA Blood Pressure guidelines! Eight years have passed since the last update. What’s different? What’s the same? Tonight we tackle it all!
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Hypertension
AIM: The “2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for
the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults”
retires and replaces the “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults.” METHODS: A comprehensive literature search was conducted from December 2023 to June 2024 to
identify clinical studies, reviews, and other evidence performed on human subjects
that were published since February 2015 in English from MEDLINE (through PubMed),
EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and
other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to create a living, working document
updating current knowledge in the field of high blood pressure aimed at all practicing
primary care and specialty clinicians who manage patients with hypertension.
www.ahajournals.org
September 16, 2025 at 11:00 PM
⏰2 hours until #NephJC chat
🔍 Tonight we are talking about the 2025 ACC/AHA Blood Pressure guidelines! Eight years have passed since the last update. What’s different? What’s the same? Tonight we tackle it all!
🔍 Tonight we are talking about the 2025 ACC/AHA Blood Pressure guidelines! Eight years have passed since the last update. What’s different? What’s the same? Tonight we tackle it all!
Reposted
AL amyloid is most often assoc. with multiple myeloma. Few case studies of AA amyloid with MM. Amyloidosis associated with MM is rare and optimal treatment is not well defined. Most patients do not live more than 6 months. Chemo for MM +\- Plasma exchange?
pubmed.ncbi.nlm.nih.gov/37664311/
pubmed.ncbi.nlm.nih.gov/37664311/
Intestinal Reactive Amyloid A (AA) Amyloidosis in a Patient With Multiple Myeloma: A Case Report and Literature Review - PubMed
Amyloidosis is a rare group of disorders characterized by the extracellular deposition of misfolded protein aggregates that interfere with the function of the tissue affected. In some patients, the pr...
pubmed.ncbi.nlm.nih.gov
April 19, 2025 at 3:00 AM
AL amyloid is most often assoc. with multiple myeloma. Few case studies of AA amyloid with MM. Amyloidosis associated with MM is rare and optimal treatment is not well defined. Most patients do not live more than 6 months. Chemo for MM +\- Plasma exchange?
pubmed.ncbi.nlm.nih.gov/37664311/
pubmed.ncbi.nlm.nih.gov/37664311/
Reposted
It’s a big day in the reporting guidelines and transparency calendar with the release of the new and revised CONSORT statement for reporting randomised trials (CONSORT-2025)
You can get the reporting recommendations here
www.bmj.com/content/389/...
#OpenAccess #ResearchIntegrity #Transparency
You can get the reporting recommendations here
www.bmj.com/content/389/...
#OpenAccess #ResearchIntegrity #Transparency
CONSORT 2025 statement: updated guideline for reporting randomised trials
Background Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the...
www.bmj.com
April 15, 2025 at 8:30 AM
It’s a big day in the reporting guidelines and transparency calendar with the release of the new and revised CONSORT statement for reporting randomised trials (CONSORT-2025)
You can get the reporting recommendations here
www.bmj.com/content/389/...
#OpenAccess #ResearchIntegrity #Transparency
You can get the reporting recommendations here
www.bmj.com/content/389/...
#OpenAccess #ResearchIntegrity #Transparency
Reposted
11/10
➡️Up next - 4/28/25 on #Bluesky: Microvascular Inflammation of Kidney Allografts and Clinical Outcomes.🔬
www.nejm.org/doi/full/10.1056/NEJMoa2408835
summary by @brianrifkin.bsky.social
➡️Up next - 4/28/25 on #Bluesky: Microvascular Inflammation of Kidney Allografts and Clinical Outcomes.🔬
www.nejm.org/doi/full/10.1056/NEJMoa2408835
summary by @brianrifkin.bsky.social
Microvascular Inflammation of Kidney Allografts and Clinical Outcomes | NEJM
The heterogeneous clinical presentation of graft microvascular inflammation poses
a major challenge to successful kidney transplantation. The effect of microvascular
inflammation on allograft outco...
www.nejm.org
April 17, 2025 at 5:57 PM
11/10
➡️Up next - 4/28/25 on #Bluesky: Microvascular Inflammation of Kidney Allografts and Clinical Outcomes.🔬
www.nejm.org/doi/full/10.1056/NEJMoa2408835
summary by @brianrifkin.bsky.social
➡️Up next - 4/28/25 on #Bluesky: Microvascular Inflammation of Kidney Allografts and Clinical Outcomes.🔬
www.nejm.org/doi/full/10.1056/NEJMoa2408835
summary by @brianrifkin.bsky.social
Reposted
Excited to share our latest publication in Kidney International Reports: "Systematic Review of Patient and Caregiver Involvement in CKD Research." Our findings highlight the need for more meaningful consumer involvement to enhance research relevance and impact. www.kireports.org/article/S246...
Systematic Review of Patient and Caregiver Involvement in Chronic Kidney Disease Research
Limited consumer involvement in chronic kidney disease (CKD) research may reduce its
relevance, impact, and transferability into practice and policy. We aimed to describe
the current landscape of cons...
www.kireports.org
March 20, 2025 at 3:32 AM
Excited to share our latest publication in Kidney International Reports: "Systematic Review of Patient and Caregiver Involvement in CKD Research." Our findings highlight the need for more meaningful consumer involvement to enhance research relevance and impact. www.kireports.org/article/S246...
#askrenal A 49 year male diagnosed with infiltrative cardiomyopathy and a negative Tc99 PYP SPECT CT scan. Kappa/Lambda - 38/1175, ⬆️ SAA. Bone marrow biopsy - 17% plasma cells. SIFE-Biclonal band - IgGLamda and IgAKappa. Kidney biopsy - AA Amyloid deposits in vessels. How to proceed?
April 18, 2025 at 7:46 AM
#askrenal A 49 year male diagnosed with infiltrative cardiomyopathy and a negative Tc99 PYP SPECT CT scan. Kappa/Lambda - 38/1175, ⬆️ SAA. Bone marrow biopsy - 17% plasma cells. SIFE-Biclonal band - IgGLamda and IgAKappa. Kidney biopsy - AA Amyloid deposits in vessels. How to proceed?
Reposted
April 2, 2025 at 1:27 PM
Reposted
Ok #NephMadness, I’ve got a few 🦴 to pick with the Filtered 4.
Novel HTN treatment? How about getting to goal with what we got!
CAR-T? Good for cancer, GN not so much yet.
Toxins over dialysis innovation? SRSLY 🫣
MCD over kidney donation? It’s called MINIMAL change for a reason.
#BlueRibbonFail
Novel HTN treatment? How about getting to goal with what we got!
CAR-T? Good for cancer, GN not so much yet.
Toxins over dialysis innovation? SRSLY 🫣
MCD over kidney donation? It’s called MINIMAL change for a reason.
#BlueRibbonFail
April 4, 2025 at 7:20 PM
Ok #NephMadness, I’ve got a few 🦴 to pick with the Filtered 4.
Novel HTN treatment? How about getting to goal with what we got!
CAR-T? Good for cancer, GN not so much yet.
Toxins over dialysis innovation? SRSLY 🫣
MCD over kidney donation? It’s called MINIMAL change for a reason.
#BlueRibbonFail
Novel HTN treatment? How about getting to goal with what we got!
CAR-T? Good for cancer, GN not so much yet.
Toxins over dialysis innovation? SRSLY 🫣
MCD over kidney donation? It’s called MINIMAL change for a reason.
#BlueRibbonFail
Reposted
#NephMadness 2025: The Left and Right Kidneys
bit.ly/NM25Finalists
@nephrosparks.bsky.social @annaburgner.bsky.social @kidneywars.bsky.social @jrkott27.bsky.social @catochita.bsky.social
bit.ly/NM25Finalists
@nephrosparks.bsky.social @annaburgner.bsky.social @kidneywars.bsky.social @jrkott27.bsky.social @catochita.bsky.social
#NephMadness 2025: The Left and Right Kidneys
We’re down to just two teams! Will the pressure bring out the best in these competitors, or will they wither under the bright lights? Check out the Current Standings and share your reactions …
bit.ly
April 7, 2025 at 12:52 PM
#NephMadness 2025: The Left and Right Kidneys
bit.ly/NM25Finalists
@nephrosparks.bsky.social @annaburgner.bsky.social @kidneywars.bsky.social @jrkott27.bsky.social @catochita.bsky.social
bit.ly/NM25Finalists
@nephrosparks.bsky.social @annaburgner.bsky.social @kidneywars.bsky.social @jrkott27.bsky.social @catochita.bsky.social
Reposted
The biggest #BlueRibbonFail of #NephMadness is CAR-T. Very cool immunology, perhaps useful in extremely severe autoimmunity, but overall impact on nephrology? Next to nil. Too toxic, too hard to scale.
two men are sitting at a table in a bowling alley with the words `` am i wrong ? '' above them .
ALT: two men are sitting at a table in a bowling alley with the words `` am i wrong ? '' above them .
media.tenor.com
April 7, 2025 at 12:29 PM
The biggest #BlueRibbonFail of #NephMadness is CAR-T. Very cool immunology, perhaps useful in extremely severe autoimmunity, but overall impact on nephrology? Next to nil. Too toxic, too hard to scale.
Reposted
@glombandit.bsky.social and Dr. Melanie Hoenig sitting in the lead! No perfect brackets remain.
#Nephmadness I just can’t buy CAR-T and MCD diagnosis as the most important issues for nephrologists in the next 5 years.
I wear my 875 out of 906 as a badge of honor 🎖️ #BlueRibbonFail
#Nephmadness I just can’t buy CAR-T and MCD diagnosis as the most important issues for nephrologists in the next 5 years.
I wear my 875 out of 906 as a badge of honor 🎖️ #BlueRibbonFail
April 7, 2025 at 5:05 PM
@glombandit.bsky.social and Dr. Melanie Hoenig sitting in the lead! No perfect brackets remain.
#Nephmadness I just can’t buy CAR-T and MCD diagnosis as the most important issues for nephrologists in the next 5 years.
I wear my 875 out of 906 as a badge of honor 🎖️ #BlueRibbonFail
#Nephmadness I just can’t buy CAR-T and MCD diagnosis as the most important issues for nephrologists in the next 5 years.
I wear my 875 out of 906 as a badge of honor 🎖️ #BlueRibbonFail
Reposted
Whoah
The CAR-T cells underdog continues to roll on and over novel therapies for hypertension
ajkdblog.org/2025/04/07/n...
A true #NephMadness #BlueRibbonFail
(But well done @melhoenig.bsky.social and @glombandit.bsky.social !)
The CAR-T cells underdog continues to roll on and over novel therapies for hypertension
ajkdblog.org/2025/04/07/n...
A true #NephMadness #BlueRibbonFail
(But well done @melhoenig.bsky.social and @glombandit.bsky.social !)
#NephMadness 2025: The Left and Right Kidneys
We’re down to just two teams! Will the pressure bring out the best in these competitors, or will they wither under the bright lights? Check out the Current Standings and share your reactions …
ajkdblog.org
April 7, 2025 at 5:26 PM
Whoah
The CAR-T cells underdog continues to roll on and over novel therapies for hypertension
ajkdblog.org/2025/04/07/n...
A true #NephMadness #BlueRibbonFail
(But well done @melhoenig.bsky.social and @glombandit.bsky.social !)
The CAR-T cells underdog continues to roll on and over novel therapies for hypertension
ajkdblog.org/2025/04/07/n...
A true #NephMadness #BlueRibbonFail
(But well done @melhoenig.bsky.social and @glombandit.bsky.social !)
Reposted
& the @nephjc.bsky.social summary of this study here: www.nephjc.com/news/bproad
It was a great journal club discussion too, 🤓🙏
It was a great journal club discussion too, 🤓🙏
BPROAD: Sprinting down the BP Road in Diabetes — NephJC
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
www.nephjc.com
March 31, 2025 at 7:58 PM
& the @nephjc.bsky.social summary of this study here: www.nephjc.com/news/bproad
It was a great journal club discussion too, 🤓🙏
It was a great journal club discussion too, 🤓🙏
Reposted
In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-pressure target of less than 120 mm Hg than with a target of less than 140 mm Hg. Full trial results and Research Summary: nej.md/4eyDckd
#MedSky #CardioSky
#MedSky #CardioSky
March 31, 2025 at 7:50 PM
In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-pressure target of less than 120 mm Hg than with a target of less than 140 mm Hg. Full trial results and Research Summary: nej.md/4eyDckd
#MedSky #CardioSky
#MedSky #CardioSky
Reposted
December 4, 2024 at 5:22 AM
Reposted
And sema for DM + PAD as well from #ACC25 in @thelancet.bsky.social
www.thelancet.com/journals/lan...
Glipination helps you walk 🚶🏽🚶🏻♀️🚶🏻♂️further
www.thelancet.com/journals/lan...
Glipination helps you walk 🚶🏽🚶🏻♀️🚶🏻♂️further
March 30, 2025 at 9:55 PM
And sema for DM + PAD as well from #ACC25 in @thelancet.bsky.social
www.thelancet.com/journals/lan...
Glipination helps you walk 🚶🏽🚶🏻♀️🚶🏻♂️further
www.thelancet.com/journals/lan...
Glipination helps you walk 🚶🏽🚶🏻♀️🚶🏻♂️further
Reposted
People look at this and scream about getting an AV accesses because of the dramatically lower infection rate, but 1.2 infections per 100 patient-years is 1.2 blood stream infections per patient per 8.8 years
We have bigger fish to fry in dialysis than one BSI per decade.
We have bigger fish to fry in dialysis than one BSI per decade.
March 31, 2025 at 1:42 AM
People look at this and scream about getting an AV accesses because of the dramatically lower infection rate, but 1.2 infections per 100 patient-years is 1.2 blood stream infections per patient per 8.8 years
We have bigger fish to fry in dialysis than one BSI per decade.
We have bigger fish to fry in dialysis than one BSI per decade.
Reposted
March 31, 2025 at 12:44 PM
Reposted
Announcing the #NephJC internship, @nephjc.bsky.social and @kireports.bsky.social joining forces
www.nephjc.com/intern-app for details and to apply!
#NephSky
www.nephjc.com/intern-app for details and to apply!
#NephSky
NephJC Editorial Internship — NephJC
www.nephjc.com
March 6, 2025 at 6:16 PM
Announcing the #NephJC internship, @nephjc.bsky.social and @kireports.bsky.social joining forces
www.nephjc.com/intern-app for details and to apply!
#NephSky
www.nephjc.com/intern-app for details and to apply!
#NephSky
Reposted
Any influence of drugs in diagnosis?
✅ laterality index > 4 → higher ARR & adrenal masses 📊
✅ Adrenalectomy → 89% biochemical cure! #NephJC
pubmed.ncbi.nlm.nih.gov/31033727/
✅ laterality index > 4 → higher ARR & adrenal masses 📊
✅ Adrenalectomy → 89% biochemical cure! #NephJC
pubmed.ncbi.nlm.nih.gov/31033727/
Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling - PubMed
Our findings suggest that in primary aldosteronism patients to whom DAPD were administrated due to severe clinical features, laterality index more than 4 in ACTH-AVS could accurately predict a biochemical cure after adrenalectomy.
pubmed.ncbi.nlm.nih.gov
February 26, 2025 at 2:43 AM
Any influence of drugs in diagnosis?
✅ laterality index > 4 → higher ARR & adrenal masses 📊
✅ Adrenalectomy → 89% biochemical cure! #NephJC
pubmed.ncbi.nlm.nih.gov/31033727/
✅ laterality index > 4 → higher ARR & adrenal masses 📊
✅ Adrenalectomy → 89% biochemical cure! #NephJC
pubmed.ncbi.nlm.nih.gov/31033727/
Reposted
Cosyntropin-Stimulated AVS: No Effect from MRAs!
💡 MRAs did NOT affect cosyntropin-stimulated AVS results!
📌 If renin suppression & stimulation tests are unaffected, why stop MRAs before AVS? #NephJC
💡 MRAs did NOT affect cosyntropin-stimulated AVS results!
📌 If renin suppression & stimulation tests are unaffected, why stop MRAs before AVS? #NephJC
February 26, 2025 at 2:47 AM
Cosyntropin-Stimulated AVS: No Effect from MRAs!
💡 MRAs did NOT affect cosyntropin-stimulated AVS results!
📌 If renin suppression & stimulation tests are unaffected, why stop MRAs before AVS? #NephJC
💡 MRAs did NOT affect cosyntropin-stimulated AVS results!
📌 If renin suppression & stimulation tests are unaffected, why stop MRAs before AVS? #NephJC
Reposted
Limitations:
📌 Design = potential confounders & selection bias
📌 Small MRA group size
Do we need more global, prospective studies to confirm? #NephJC
📌 Design = potential confounders & selection bias
📌 Small MRA group size
Do we need more global, prospective studies to confirm? #NephJC
a dog looking at the earth with a colorful background
ALT: a dog looking at the earth with a colorful background
media.tenor.com
February 26, 2025 at 2:50 AM
Limitations:
📌 Design = potential confounders & selection bias
📌 Small MRA group size
Do we need more global, prospective studies to confirm? #NephJC
📌 Design = potential confounders & selection bias
📌 Small MRA group size
Do we need more global, prospective studies to confirm? #NephJC
Reposted
🎯 A Step Closer to Precision Medicine?
Despite limitations, this study encourages a more tailored approach:
✅ AVS in high-risk PA without worrying about MRA use.
✅ Identify truly curable hypertensives.
Are we moving towards a more individualized PA workup? #NephJC
Despite limitations, this study encourages a more tailored approach:
✅ AVS in high-risk PA without worrying about MRA use.
✅ Identify truly curable hypertensives.
Are we moving towards a more individualized PA workup? #NephJC
February 26, 2025 at 2:51 AM
🎯 A Step Closer to Precision Medicine?
Despite limitations, this study encourages a more tailored approach:
✅ AVS in high-risk PA without worrying about MRA use.
✅ Identify truly curable hypertensives.
Are we moving towards a more individualized PA workup? #NephJC
Despite limitations, this study encourages a more tailored approach:
✅ AVS in high-risk PA without worrying about MRA use.
✅ Identify truly curable hypertensives.
Are we moving towards a more individualized PA workup? #NephJC
Reposted
AVS is still key to identifying surgical candidates. Time to screen more aggressively? #NephJC
pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov/articles/PMC...
Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis
Superior outcomes after surgical treatment over medical treatment for primary aldosteronism (PA) has been reported in small-scale clinical studies, but no solid conclusion has been drawn as results of...
pmc.ncbi.nlm.nih.gov
February 26, 2025 at 2:52 AM
AVS is still key to identifying surgical candidates. Time to screen more aggressively? #NephJC
pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov/articles/PMC...